Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia-Reference-Cited by-同舟云学术

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia

Published:2016-07-04 Issue:9 Volume:95 Page:1503-1512
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Burkhardt Birgit,Yavuz Deniz,Zimmermann Martin,Schieferstein Jutta,Kabickova Edita,Attarbaschi Andishe,Lisfeld Jasmin,Reiter Alfred,Makarova Olga,Worch Jennifer,Bonn Bettina R.,Damm-Welk Christine

Funder

Czech Ministry of Health

Forschungshilfe Peiper

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2731-x.pdf

Reference42 articles.

1. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C, Committee FLIS (2008) Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 141(6):840–847. doi: 10.1111/j.1365-2141.2008.07144.x

2. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109(7):2736–2743. doi: 10.1182/blood-2006-07-036665

3. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS, Committee FLIS (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109(7):2773–2780. doi: 10.1182/blood-2006-07-036673

4. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, Group BFM (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105(3):948–958. doi: 10.1182/blood-2004-03-0973

5. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphael M, Terrier-Lacombe MJ (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97(11):3370–3379. doi: 10.1182/blood.V97.11.3370

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-06

2. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody;Frontiers in Immunology;2022-08-31

3. An anti-CTLA-4 heavy chain–only antibody with enhanced T _reg depletion shows excellent preclinical efficacy and safety profile;Proceedings of the National Academy of Sciences;2022-08-04

4. Patient parameters and response after administration of rituximab in pediatric mature B‐cell non‐Hodgkin lymphoma;Pediatric Blood & Cancer;2021-12-22

5. Biologics in autoimmune bullous diseases: Current scenario;Indian Journal of Dermatology, Venereology and Leprology;2021-07-01